Pfizer Inc. (NYSE: PFE), a pharmaceutical titan based in the US, has announced encouraging topline results from a sub-study within its ongoing Phase III clinical trial (NCT05842967) for Abrysvo, a vaccine designed to combat respiratory syncytial virus (RSV). The data indicate that Abrysvo offers robust protection against RSV infections in immunocompromised adults, a demographic that encompasses cancer patients and those with autoimmune conditions, who are at a significantly higher risk of severe RSV-related complications. This trial is pioneering, marking the first time that data has been collected for an RSV vaccine catered specifically to this vulnerable patient group.
Abrysvo received its initial approval in the US in May 2023 for the prevention of RSV in older adults. Subsequently, in August 2023, it was approved for the prevention of RSV in infants through active immunization of pregnant individuals between 32-36 weeks of gestational age.- Flcube.com
